Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillatio

Phase 4

• Conditions: atrial fibrillation; 10007521

• Registration Number: NL-OMON37797
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

- patients presenting with paroxysmal or persistent AF;- eligible for treatment with flecainide or vernakalant infusion to restore sinus rhythm;- receiving adequate anticoagulant therapy (or having an episode of AF lasting < 24 hours)

Exclusion Criteria

- atrial flutter;- contra-indications for receiving flecainide or vernakalant infusion according to MUMC+ protocol (unstable hemodynamic condition, LVEF < 40%, inadequate potassium levels, acute ischaemia, sinus node dysfunction);- age < 18 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Echocardiography to evaluate atrial contractility after conversion to sinus<br /><br>rhythm </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>2a. conversion rate to sinus rhythm<br /><br>2b. recurrence of AF at one month follow-up</p><br>